London, United Kingdom (PressExposure) March 08, 2011 -- GlobalData has estimated the global gout therapeutics market to be valued at $854m in 2010. It is forecast to grow at a CAGR (Compound Annual Growth Rate) of 12% for the next seven years to reach $1.8 billion by 2017. The market grew at a CAGR of 7% during the historic period (2005-2010). The major breakthrough in the otherwise dormant gout market was the approval of Uloric (febuxostat) after 40 years by the EMEA (European Medicines Agency) in 2008 and by the FDA (Foods and Drug Administration) in 2009. Krystexxa also got approval in September 2010, for the treatment of refractory gout. The increasing patient population and expected launch of few biologics and newer therapies during the forecast period will drive the market growth
GlobalData analyzed the current competition in the gout market and found it to be quite weak. Currently, Zyloprim (allopurinol) is the market leader in terms of prescribed drugs for the treatment of chronic gout. Uloric (febuxostat), which was approved by the EMEA (European Medicines Agency) in 2008 and by the FDA (Foods and Drug Administration) in 2009 is used as a second line option in patients who are intolerant to allopurinol. According to NICE (National Institute for Health and Clinical Excellence) guidelines, even though Uloric is more effective than allopurinol it has not been shown to be more cost effective than the titrating doses of allopurinol.
Another treatment option, Krystexxa (pegloticase), which was recently approved by the FDA for the treatment of refractory chronic gout, will serve only a specific patient pool that experiences treatment failure with the standard treatment options, such as allopurinol and febuxostat. It is also a well established fact that almost 80-90% of gout patients have hyperuricemia because of the problem of the under-excretion of uric acid from the body while only 10-15% patients have hyperuricemia due to the over-production of uric acid. However, currently the major treatment options available in the chronic gout segment targets the reduction of the over-production of uric acid. There is a huge set of patients waiting for newer therapies to treat the problem of the under-excretion of uric acid, as well the development of safe and efficacious drugs for the treatment of gout flares.
For Sample Pages, please click or add the below link to your browser:
development. There are nine first-in-class molecules over all of the phases of development, which means that 70% of the pipeline molecules have a novel mechanism of action. Arcalyst (rilonacept), ACZ885 (canakinumab) and RDEA594 are the promising molecules in the late stage pipeline. Out of these, Arcalyst and ACZ885 are expected to have better efficacy and safety for the treatment of gout flares, and hence they are expected to increase the patient compliance rate. Both of the drugs are biologics and are expected to be highly priced.
Currently, 54% of the total gout pipeline is in the Phase II and Phase III stages of development, which suggests a strong pipeline. This implies that the competition in the future market is set to increase as new therapies enter the market to cater for the unmet needs of the patients in terms of safety and efficacy.
GlobalData, the industry analysis specialist, has released its new report, "Gout Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global Gout therapeutics market. The report identifies the key trends shaping and driving the global Gout therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Gout sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
For further details, please click or add the below link to your browser:
Visit our report store: http://www.globaldata.com